However, when focusing on patients with M-CLL and wild-type in the TP53 gene, those with at least one ALT allele had a higher EFS compared to homozygous REF patients (10-year EFS: 67% carriers vs. 59% non-carriers, p-value = 0.04, Fig. 3d). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.